SCHOLAR ROCK HOLDING CORPORATION Investing Cash Flow
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Investing Cash Flow of -$10.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$5.50M, a 106.44% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$5.33M, a 115.44% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $38.97M.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $59.70M, a 69.08% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) investing activities for fiscal 2025 was $218.69M.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) investing activities for fiscal 2024 was -$76.06M, a 284.87% decline from fiscal 2023.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) investing activities for fiscal 2023 was $41.14M.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) investing activities for fiscal 2022 was -$171.70M, a 227.83% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$10.84M 10-Q · filed 2026-08-06 | $28.13M derived: sum of 3 quarters · filed 2026-08-06 | $87.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$5.33M 10-Q · filed 2026-05-07 | $33.63M derived: sum of 2 quarters · filed 2026-05-07 | $93.33M derived: sum of 3 quarters · filed 2026-05-07 | $178.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $38.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $98.67M derived: sum of 2 quarters · filed 2026-03-03 | $184.13M derived: sum of 3 quarters · filed 2026-08-06 | $218.69M 10-K · filed 2026-03-03 |
| 2025-09-30 | $59.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $145.16M derived: sum of 2 quarters · filed 2026-08-06 | $179.72M 10-Q · filed 2025-11-14 | -$15.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $85.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $120.02M 10-Q · filed 2026-08-06 | -$75.35M derived: sum of 3 quarters · filed 2026-08-06 | -$40.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $34.55M 10-Q · filed 2026-05-07 | -$160.82M derived: sum of 2 quarters · filed 2026-05-07 | -$125.51M derived: sum of 3 quarters · filed 2026-05-07 | -$74.89M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$195.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$160.06M derived: sum of 2 quarters · filed 2026-03-03 | -$109.44M derived: sum of 3 quarters · filed 2026-03-03 | -$76.06M 10-K · filed 2026-03-03 |
| 2024-09-30 | $35.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $85.93M derived: sum of 2 quarters · filed 2025-11-14 | $119.31M 10-Q · filed 2025-11-14 | $94.19M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $50.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $84.01M 10-Q · filed 2025-08-06 | $58.88M derived: sum of 3 quarters · filed 2025-08-06 | $50.41M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $33.38M 10-Q · filed 2025-05-14 | $8.26M derived: sum of 2 quarters · filed 2025-05-14 | -$217.00K derived: sum of 3 quarters · filed 2025-05-14 | -$15.46M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$25.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$33.60M derived: sum of 2 quarters · filed 2025-02-27 | -$48.84M derived: sum of 3 quarters · filed 2025-02-27 | $41.14M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$8.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$23.71M derived: sum of 2 quarters · filed 2024-11-12 | $66.27M 10-Q · filed 2024-11-12 | $66.35M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$15.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $74.74M 10-Q · filed 2024-08-08 | $74.82M derived: sum of 3 quarters · filed 2024-08-08 | -$70.90M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $89.98M 10-Q · filed 2024-05-07 | $90.06M derived: sum of 2 quarters · filed 2024-05-07 | -$55.66M derived: sum of 3 quarters · filed 2024-05-07 | -$11.14M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$145.64M derived: sum of 2 quarters · filed 2024-03-19 | -$101.12M derived: sum of 3 quarters · filed 2024-03-19 | -$171.70M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$145.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$101.20M derived: sum of 2 quarters · filed 2023-11-07 | -$171.78M 10-Q · filed 2023-11-07 | -$142.32M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $44.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$26.05M 10-Q · filed 2023-08-09 | $3.40M derived: sum of 3 quarters · filed 2023-08-09 | $6.69M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$70.58M 10-Q · filed 2023-05-09 | -$41.12M derived: sum of 2 quarters · filed 2023-05-09 | -$37.84M derived: sum of 3 quarters · filed 2023-05-09 | $41.18M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $29.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $32.74M derived: sum of 2 quarters · filed 2023-03-07 | $111.76M derived: sum of 3 quarters · filed 2023-03-07 | $134.31M 10-K · filed 2023-03-07 |
| 2021-09-30 | $3.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $82.30M derived: sum of 2 quarters · filed 2022-11-14 | $104.86M 10-Q · filed 2022-11-14 | -$17.78M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $79.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $101.57M 10-Q · filed 2022-08-08 | -$21.07M derived: sum of 3 quarters · filed 2022-08-08 | -$56.94M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $22.56M 10-Q · filed 2022-05-16 | -$100.08M derived: sum of 2 quarters · filed 2022-05-16 | -$135.96M derived: sum of 3 quarters · filed 2022-05-16 | -$97.03M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$122.64M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | -$158.51M derived: sum of 2 quarters · filed 2022-03-07 | -$119.59M derived: sum of 3 quarters · filed 2022-03-07 | -$63.50M 10-K · filed 2022-03-07 |
| 2020-09-30 | -$35.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $3.05M derived: sum of 2 quarters · filed 2021-11-09 | $59.14M 10-Q · filed 2021-11-09 | $80.35M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $38.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $95.02M 10-Q · filed 2021-08-10 | $116.23M derived: sum of 3 quarters · filed 2021-08-10 | $44.06M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $56.09M 10-Q · filed 2021-05-13 | $77.30M derived: sum of 2 quarters · filed 2021-05-13 | $5.13M derived: sum of 3 quarters · filed 2021-05-13 | $26.23M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $21.21M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$50.96M derived: sum of 2 quarters · filed 2021-03-09 | -$29.86M derived: sum of 3 quarters · filed 2021-03-09 | -$62.24M 10-K · filed 2021-03-09 |
| 2019-09-30 | -$72.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$51.07M derived: sum of 2 quarters · filed 2020-11-09 | -$83.44M 10-Q · filed 2020-11-09 | -$144.38M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $21.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$11.28M 10-Q · filed 2020-08-07 | -$72.22M derived: sum of 3 quarters · filed 2020-08-07 | -$72.81M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | -$32.38M 10-Q · filed 2020-05-07 | -$93.32M derived: sum of 2 quarters · filed 2020-05-07 | -$93.92M derived: sum of 3 quarters · filed 2020-05-07 | -$69.02M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$60.94M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$61.54M derived: sum of 2 quarters · filed 2020-03-12 | -$36.64M derived: sum of 3 quarters · filed 2020-03-12 | -$60.23M 10-K · filed 2020-03-12 |
| 2018-09-30 | -$598.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $24.30M derived: sum of 2 quarters · filed 2019-11-12 | $708.00K 10-Q · filed 2019-11-12 | $6.61M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $24.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $1.31M 10-Q · filed 2019-08-14 | $7.20M derived: sum of 3 quarters · filed 2019-08-14 | $16.18M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | -$23.59M 10-Q · filed 2019-05-15 | -$17.69M derived: sum of 2 quarters · filed 2019-05-15 | -$8.71M derived: sum of 3 quarters · filed 2019-05-15 | |
| 2017-12-31 | $5.90M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-19 | $14.87M derived: sum of 2 quarters · filed 2019-03-19 | $17.66M 10-K · filed 2019-03-19 | |
| 2017-09-30 | $8.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $11.77M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $2.79M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |